Differential expression of N‐glycopeptides derived from serum glycoproteins in mild cognitive impairment (MCI) patients
Authors:
- 11 April 2024
- journal article
- research article
- Published by Wiley in Proteomics
- Vol. 24 (20) , e2300620
Abstract
Mild cognitive impairment (MCI) is an early stage of memory loss that affects cognitive abilities with the aging of individuals, such as language or visual/spatial comprehension. MCI is considered a prodromal phase of more complicated neurodegenerative diseases such as Alzheimer's. Therefore, accurate diagnosis and better understanding of the disease prognosis will facilitate prevention of neurodegeneration. However, the existing diagnostic methods fail to provide precise and well‐timed diagnoses, and the pathophysiology of MCI is not fully understood. Alterations of the serum N‐glycoproteome expression could represent an essential contributor to the overall pathophysiology of neurodegenerative diseases and be used as a potential marker to assess MCI diagnosis using less invasive procedures. In this approach, we identified N‐glycopeptides with different expressions between healthy and MCI patients from serum glycoproteins. Seven of the N‐glycopeptides showed outstanding AUC values, among them the antithrombin‐III Asn224 + 4‐5‐0‐2 with an AUC value of 1.00 and a p value of 0.0004. According to proteomics and ingenuity pathway analysis (IPA), our data is in line with recent publications, and the glycoproteins carrying the identified N‐sites play an important role in neurodegeneration.Keywords
Funding Information
- National Institutes of Health (1R01GM112490‐08(YM), 1R01GM130091‐05(YM), 1U01CA225753‐05(YM/DML))
This publication has 80 references indexed in Scilit:
- Advances in mass spectrometry‐based glycoproteomics: An update covering the period 2017–2021Electrophoresis, 2021
- Glycomics and glycoproteomics: Approaches to address isomeric separation of glycans and glycopeptidesJournal of Separation Science, 2020
- Advances in mass spectrometry‐based glycomicsElectrophoresis, 2018
- High complement levels in astrocyte‐derived exosomes of Alzheimer diseaseAnnals of Neurology, 2018
- LC‐MS/MS isomeric profiling of permethylated N‐glycans derived from serum haptoglobin of hepatocellular carcinoma (HCC) and cirrhotic patientsElectrophoresis, 2017
- Identification and validation of novel CSF biomarkers for early stages of Alzheimer's diseaseProteomics – Clinical Applications, 2007
- Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical TrialsArchives of Neurology, 2004
- Current Concepts in Mild Cognitive ImpairmentArchives of Neurology, 2001
- Protein glycosylation in development and diseaseBioEssays, 1999
- Mild Cognitive ImpairmentArchives of Neurology, 1999